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Abstract
Background: Plants may represent excellent alternatives to classical heterologous protein
expression systems, especially for the production of biopharmaceuticals and vaccine components.
Modern vaccines are becoming increasingly complex, with the incorporation of multiple antigens.
Approaches towards developing an HIV vaccine appear to confirm this, with a combination of
candidate antigens. Among these, HIV-Nef is considered a promising target for vaccine
development because immune responses directed against this viral protein could help to control
the initial steps of viral infection and to reduce viral loads and spreading. Two isoforms of Nef
protein can be found in cells: a full-length N-terminal myristoylated form (p27, 27 kDa) and a
truncated form (p25, 25 kDa). Here we report the expression and purification of HIV Nef from
transgenic tobacco.
Results: We designed constructs to direct the expression of p25 and p27 Nef to either the cytosol
or the secretory pathway. We tested these constructs by transient expression in tobacco
protoplasts. Cytosolic Nef polypeptides are correctly synthesised and are stable. The same is not
true for Nef polypeptides targeted to the secretory pathway by virtue of a signal peptide. We
therefore generated transgenic plants expressing cytosolic, full length or truncated Nef. Expression
levels were variable, but in some lines they averaged 0.7% of total soluble proteins. Hexahistidine-
tagged Nef was easily purified from transgenic tissue in a one-step procedure.
Conclusion: We have shown that transient expression can help to rapidly determine the best
cellular compartment for accumulation of a recombinant protein. We have successfully expressed
HIV Nef polypeptides in the cytosol of transgenic tobacco plants. The proteins can easily be purified
from transgenic tissue.
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Plants have emerged as a safe and economical alternative
to mainstream protein expression systems based on the
large-scale culture of microbes or animal cells or on trans-
genic animals to produce biopharmaceuticals. Diverse,
complex macromolecules such as antibodies [1,2] and
vaccine components [3] have been successfully expressed
in plant cells. The possibility to produce biopharmaceuti-
cals using plants offers solutions to some of the problems
associated to traditional heterologous expression systems.
For example, the bacterial production of biologically
active, complex multimeric proteins such as antibodies is
limited by the absence of the enzymatic machinery
involved in post-translational modification of newly-syn-
thesised proteins [1,2]. Among eukaryotic expression sys-
tems, yeast is not always appropriate as
hyperglycosylation of the final product is often encoun-
tered, even if several laboratories are in the process of
modulating glycosylation pathways to obtain humanized
yeast-derived glycoproteins [4,5]. Insect and mammalian
cell cultures represent complex expression platforms
requiring expensive procedures and may be easily con-
taminated with toxins, viruses or prions, raising concerns
on the safety of the final product. The plant secretory
pathway, on the other hand, has been shown to be partic-
ularly suitable for the production and accumulation of
high amounts of heterologous proteins [6,7].
Modern vaccines are becoming increasingly complex,
with several constituted by a combination of multiple
antigens. Most of the current strategies for vaccination
against HIV/AIDS involve targeting a combination of HIV
and host antigens [8]. Plant-based expression of a number
of these candidates has already been achieved, including
HIV-1 gp120 envelope glycoprotein [8], p24 core protein
[9] and the regulatory Tat protein [10].
Both regulatory and accessory HIV proteins are currently
regarded as promising targets for vaccine development as
they could provide further protective efficacy in combina-
tion with viral structural proteins. For this purpose, HIV-1
accessory Nef protein is considered a promising target for
vaccine development [11].
Nef is incorporated into viral particles and expressed in
the early stage of infection both in the cytoplasm and on
the cell membrane of virus-infected cells. Nef interacts
with multiple host factors in order to optimise the cellular
environment for virus replication [12]. Its critical role for
viral pathogenicity is demonstrated by the fact that the
infection with nef-defective HIV strains dramatically
decreases the rate of disease progression in seropositive
individuals [13]. Moreover, Nef is an important compo-
nent for CTL-based HIV-1 vaccines. For this reason
immune responses directed against this viral protein
could help to control the initial steps of viral infection and
to reduce viral loads and spreading [11].
In vitro proteolysis experiments have shown that Nef con-
sists of an N-terminal membrane anchor region and a well
folded C-terminal core domain [14]. The N-terminal
membrane anchor domain structure has been solved in its
myristoylated and non-myristoylated forms showing a
flexible polypeptide chain with two helical structure ele-
ments [15].
When translated in vitro, the Nef gene yields two main
polypeptides: a full-length N-terminal myristoylated form
of 27 kDa (p27) and a truncated form of 25 kDa (p25)
translated from a second start codon of the Nef gene and
lacking the first 18 amino acids. Non-myristoylated p27
Nef mutant and p25 Nef were both found in the cyto-
plasm, while the wild-type, presumably myristoylated
p27 Nef was mainly membrane associated [16]. Both p27
and p25 have been expressed in different biological sys-
tems. While the levels of p27 non-myristoylated expres-
sion in E. coli are reasonably high [17], protein yield in
yeast and insect cells is very poor [18]. In particular, from
the analysis of subcellular localization of the recombinant
protein in yeast, it appears that the myristoylated form of
Nef causes cell membranes perturbation [19]. Moreover,
it has been shown that Nef expressed in transfected mam-
malian cell lines can be cytotoxic and cytostatic [20].
To explore the possibility of Nef expression in plants, we
attempted a number of different strategies. We designed a
panel of constructs to direct the expression of Nef
polypeptides to either the cytosol or the secretory path-
way. We tested these constructs initially by transient
expression in tobacco protoplasts, to rapidly ascertain the
most promising strategy for Nef production in stable
transgenic plants. Plant protoplast transfection is an
established in vivo approach that allows rapid assessment
of heterologous protein expression in plant cells [21].
Moreover it allows for an accurate assessment of the intra-
cellular fate of cytosolic or ER targeted recombinant pro-
teins [22]. Here, we report the expression of the p25 and
p27 HIV Nef polypeptides and of their non-myristoylated
p27 variants.
Results
Nef is stable in the plant cytosol
We set out to evaluate the ability of plant cells to cope
with the synthesis of Nef. We generated a number of con-
structs for Nef expression in the plant cytosol or secretory
pathway (Fig. 1). To facilitate immunodetection of the
viral polypeptides, all constructs bore the FLAG and 6×
histidine epitope tags at their C-termini, with the excep-
tion of wild-type p27 Nef that only carried the FLAG tag.
We tested these constructs by transient expression inPage 2 of 12
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analysis. We initially expressed the cytosolic forms of Nef:
full length, both with (p27) or without (p27 mut) its N-
terminal myristoylation signal, and truncated form (p25).
Transfected protoplasts were metabolically labelled with
35S-methionine and 35S-cysteine and chased for 5 hours.
Protoplast homogenates were then subjected to immuno-
precipitation with anti FLAG antiserum. SDS-PAGE and
fluorography revealed that all three constructs are success-
fully expressed, yielding polypeptides of the expected
sizes (Fig. 2). Note that p27 is faster migrating than p27
mut as it does not contain the additional histidine tag
(Fig. 2, compare lanes 4–5 with lanes 2–3). All proteins
appeared to be stable over the course of the 5-hour chase.
We wanted to investigate whether p27 was actually myrys-
toylated and able to interact with membranes. We there-
fore transfected protoplasts with plasmids encoding p25,
p27 and p27 mut. After labelling, protoplasts were
homogenised in 12% sucrose and total membranes pel-
leted. Most of the immunoselected Nef polypeptides were
retrieved in the soluble fraction (Fig. 3, lower panel, S). As
a control for microsomal membrane integrity, the endo-
plasmic reticulum-resident chaperone BiP (Fig. 3, upper
panel) was mainly immunoselected from the membrane
fractions (M). A slightly higher proportion of p27 was
found in the membrane fraction than p27 mut (Fig. 3,
compare lanes 2 and 5 with lanes 14 and 17). This indi-
cates that a very small amount of p27 may indeed be
membrane-associated, possibly via myristoylation. In any
case, it appears that the vast majority of plant-made Nef is
soluble and therefore unlikely to bear lipid modifications.
Nef is unstable in the plant secretory pathway
Having established that Nef is stable when expressed in
the cytosol, we tested whether it was possible to express
Nef in the secretory pathway. Therefore we fused the
cDNAs for both p27 and p25 to the signal peptide (sp) of
the PR1 protein [23] (constructs sp-p27 and sp-p25, Fig.
1). We have previously used this peptide successfully to
drive the expression of immunoglobulin chains in
tobacco cells [21]. We expressed the signal peptide fusions
in tobacco protoplasts and subjected cells to 2 hours con-
tinuous labelling followed by homogenisation, immuno-
precipitation with anti-FLAG antiserum, SDS-PAGE and
fluorography. Figure 4A shows that both sp-p25 and sp-
p27 are expressed and that their mobility is significantly
reduced as compared to the cytosolic forms (Fig. 4A, note
the size shift between lanes 1–2 and 3–4). Analysis of the
Nef polypeptide sequence reveals the presence of two
sequons that would be recognised as glycosylation sites
upon translocation in the lumen of the endoplasmic retic-
Diagram of the constructs used in this studyFigure 1
Diagram of the constructs used in this study. All Nef variants were under control of the CaMV 35S promoter. Sp: PR1 signal 
peptide; club: myristoylation site; tridents: predicted glycosylation sites; ∆g: unglycosylated Nef forms. P27: nef full-length 
cDNA; p27 mut: mutated form of the p27 cDNA in which the myristoylation consensus sequence is abolished; p25: nef cDNA 
encoding truncated Nef.
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Nef is expressed and is stable in the cytosol of tobacco protoplastsFigure 2
Nef is expressed and is stable in the cytosol of tobacco protoplasts. Tobacco mesophyll protoplasts were transfected with 
plasmids encoding the p27, p25 and p27 mut Nef variants, or with empty vector (Co). Transfected cells were labelled for 1 h 
with 35S methionine and cysteine and chased for 5 h with unlabelled amino acids. Cell homogenates were subjected to immu-
noprecipitation with anti-FLAG antiserum, followed by SDS-PAGE and fluorography. Numbers at left indicate molecular weight 
markers in kDa.
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ferent electrophoretic mobility of the sp-Nef fusions. In
order to prevent glycosylation – which of course does not
occur during HIV infection – from interfering with the
folding of the normally cytosolic, unglycosylated Nef pro-
tein, we inactivated the glycosylation sites by mutagenesis
(constructs sp-p27∆gly and sp-p25 ∆gly Fig. 1). We
expressed these constructs in tobacco protoplasts and sub-
jected cells to a 1-hour pulse labelling, followed by a 5-
hour chase (Fig. 4B). Remarkably, both sp-p25 and sp-
p27 resulted highly unstable, with their levels decreasing
sharply during the 5-hour chase period (Fig. 4B, lanes 3–
4 and 7–8). sp-p25∆gly showed increased mobility, as
expected by removal of the glycosylation sites (Fig 4B,
compare lanes 3–4 with lanes 5–6), but also disappeared
during the chase. Expression of p27∆gly was barely detect-
able from the outset (Fig. 4B, lanes 9–10). None of the sp-
Nef polypeptides appeared with time in the protoplast
incubation medium (data not shown), indicating that sp-
Nef fusions are capable of entering the secretory pathway
(as indicated by glycosylation) but are not at all secreted.
This phenotype – lack of secretion and fast intracellular
degradation – indicates that the Nef polypeptides may be
subject to strict quality control and subsequently disposed
of by the secretory pathway [24-27]. Certainly the amount
of 'secretory' Nef recovered after the chase did not com-
pare favourably with the levels of cytosolically expressed
protein. Targeting of Nef to the plant secretory pathway
therefore proved to be a less successful strategy than
cytosolic expression. For this reason we employed the
cytosolic construct to generate stable transgenic tobacco
plants.
Stable Nef expression in transgenic tobacco and affinity 
purification
The sequences encoding p25 and p27 mut HIV-1 Nef var-
iants were cloned into the binary plant expression vector
pBI121 and the constructs p25 and p27 mut (Fig.1) used
to generate transgenic tobacco plants. The putative trans-
genic tobacco plants were analysed by polymerase chain
reaction (PCR) to verify the nuclear integration of nef gene
(data not shown). Seventy p25 and 118 p27 mut lines
were analysed, among these 67 and 115 respectively were
positive for nef gene (data not shown).
We analysed the levels of Nef protein expression by direct
ELISA, using as primary antibody the antiserum to HIV-1
Nef (Fig. 5A–B). In these assays E.coli recombinant Nef
was used as positive control. Fifteen p27 mut and 6 p25
lines were found to express Nef variants in detectable
amounts. Among these, 3 lines expressing p27 mut (Fig.
5A, lines 64, 112, 116) and two lines expressing p25 (Fig.
5B, lines 79, 120) were further analysed to estimate Nef
expression levels. We estimated the overall amounts of
plant recombinant Nef – expressed as percentage of total
soluble plant protein (TSP) – by using a standard curve
generated with different concentrations of E.coli-produced
recombinant Nef. As shown in Fig. 5C, the quantitative
ELISA revealed variable expression levels of p25 and p27
mut Nef variants in TSP from individual transgenic lines
ranging between 0.18% of TSP (Fig. 5C, p27 mut-116)
and 0.7% (Fig. 5C, p25–79).
In order to assess the integrity of the plant-expressed Nef
polypeptides, we collected tissue samples from plants
expressing p25 or p27 mut and subjected them to SDS-
PAGE alongside increasing concentrations of a FLAG-
tagged anti-lysozyme ScFv [28] as a quantitative control
(Fig. 6A). Immunoblot with anti FLAG antiserum revealed
an immunoreactive polypeptide of the size predicted for
both p25 and p27 mut and showed clear accumulation of
the proteins. In addition, a large amount of faster migrat-
ing immunoreactive peptides were also detected. As these
are not present in samples from control plants containing
empty vector, they are likely to be degradation products of
the Nef polypeptide.
We took advantage of the 6× histidine tag appended to
p27 mut to perform a small-scale purification of Nef by
loading homogenates from transgenic leaf sections on a
cobalt affinity purification column. Immunoblot with
anti FLAG antiserum (Fig. 6B) shows that the eluate from
this one-step procedure yields an anti FLAG-immunoreac-
tive polypeptide of the size expected for p27 mut. No deg-
radation products are detected, indicating that the
purified protein is stable.
Discussion and conclusion
We have assessed a number of strategies for the expression
of HIV Nef in planta. We initially used tobacco mesophyll
protoplast transfection to test constructs encoding full-
length Nef, with (p27) or without its myristoylation sig-
nal (p27 mut), or truncated Nef (p25). The use of proto-
plast transfection, coupled with metabolic labelling and
pulse-chase experiments, allowed us to very rapidly deter-
mine what intracellular location was most suitable for
expression of Nef. Our results indicate that cytosolic Nef
polypeptides are correctly synthesised and relatively sta-
ble over a 5-hour time course. The same was not true for
Nef polypeptides targeted to the secretory pathway by vir-
tue of a signal peptide. Although the proteins translocated
correctly into the lumen of the endoplasmic reticulum, as
demonstrated by efficient N-glycosylation, they were not
stable. Moreover, there was no evidence for secretion of
any of the proteins. Even the removal of the glycosylation
sites did not significantly improve stability, or promote
secretion. Although redirection of cytosolic proteins into
the lumen of the secretory pathway has often achieved
high yield of recombinant protein [29-32] it is possible
that Nef, which is normally located in the cytosol or inPage 5 of 12
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brane [16], does not fold correctly within the milieu of the
endoplasmic reticulum. The fact that no polypeptides are
secreted and that degradation seems to occur very rapidly
indicate that Nef may be disposed of by ER quality control
mechanisms [26,33].
Our data indicate that cytosolic expression is a more
promising strategy. We therefore generated transgenic
plants expressing full length or truncated Nef. Expression
levels were variable, but in some lines they averaged 0.7%
of total soluble proteins. This is in line with a number of
other heterologous proteins expressed in transgenic
tobacco [34]. Moreover, it is possible that the ELISA values
represent an underestimate. We have indeed found that
plant protein homogenates partially interfere with the
detection of recombinant Nef in ELISA assay: by mixing
recombinant E.coli HIV-1 Nef with control plant protein
extracts, we often observed a significant reduction in the
ELISA reading as compared with the Nef protein in buffer
alone (data not shown).
Interestingly, cytosolically expressed Nef is almost com-
pletely non-myristoylated, as indicated by poor mem-
brane partitioning of Nef p27. This is somewhat
surprising, as the N-terminal myristoylation machinery is
conserved in plants [35,36]. In any case, the lack of myris-
toylation is actually beneficial to the immunogenic prop-
erties of Nef for the application in a multi-component
vaccine [37]. Indeed, deletion or mutagenesis of the N-ter-
minal myristoylation site has been shown to abrogate the
capacity of Nef to down-regulate both MHC class I and
CD4 cell-surface molecules [38], which normally prevents
CTL-mediated lysis of HIV-1-primary infected cells [39].
Therefore the lack of myristoylation is likely to elicit
enhanced cellular immune responses.
Plant-expressed Nef could be purified easily from trans-
genic leaves using a cobalt affinity column. This indicates
that the hexahistidine tag is correctly exposed in the plant-
made polypeptides. This ease of purification, together
with our data showing that cytosolic Nef expression levels
in planta are satisfactory, constitutes a useful starting point
for further optimisation and scale-up of expression. This
will allow us to analyse the biological activity and in vitro/
in vivo immunological properties of plant-produced Nef
proteins.
Methods
Recombinant DNA
The pSCNef51 (ARP#2015 NIBSC-CFAR MRC) plasmid
was used as the source of Nef cDNA (HIV-1 BH10 strain).
Cytosolic Nef variants are predominantly solubleFigure 3
Cytosolic Nef variants are predominantly soluble. Protoplasts transfected with the indicated plasmids were pulse labelled for 1 
h and chased for 5 h. Cells were then homogenised in 12% (w/w) sucrose and homogenates were fractionated by centrifuga-
tion at 100,000 g for 30 min on a 17% sucrose pad. Total homogenates (T), membrane pellets (M) and soluble supernatant (S) 
fractions were then immunoprecipitated with anti BiP (upper panel) or anti FLAG (lower panel) antisera. Numbers at left indi-
cate molecular weight markers in kDa.
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sp-Nef constructs are unstable in tobacco protoplastsFigure 4
sp-Nef constructs are unstable in tobacco protoplasts. A: Protoplasts transfected with the indicated plasmids were pulse 
labelled for 2 h. Cell homogenates were subjected to immunoprecipitation with anti-FLAG antiserum, followed by SDS-PAGE 
and fluorography. Note the size difference between cytosolic p25 and p27 (as indicated by arrowheads) and their signal-peptide 
fusion counterparts. Numbers at left indicate molecular weight markers in kDa. B: Protoplasts transfected with the indicated 
plasmids were pulse labelled for 1 h and chased for 5 h. Cell homogenates were subjected to immunoprecipitation with anti-
FLAG antiserum, followed by SDS-PAGE and fluorography. Arrowhead: aglycosylated Nef p25 (sp-p25∆g).
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ELISA analysis of transgenic tobacco plants expressing cytosolic NefFigure 5
ELISA analysis of transgenic tobacco plants expressing cytosolic Nef. A:Representative ELISA assay of p27 mut Nef tobacco 
lines. C+: 100 ng of E.coli recombinant Nef; C-: control plant, untrasformed tobacco. The numbers on the x axis indicate indi-
vidual transgenic tobacco lines. B:Representative ELISA assay of p25 Nef tobacco lines. C+: 100 ng of E.coli recombinant Nef; 
C-: control plant, untrasformed tobacco. The numbers on the x axis indicate individual transgenic tobacco lines. C: ELISA quan-
tification of plant-expressed Nef variants. The Nef expression levels are expressed as percentage of total soluble protein (TSP) 
from transgenic plants. The values shown represent averages of two experiments. The numbers on the x axis indicate individ-
ual transgenic tobacco lines.
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Analysis and affinity purification of plant-produced cytosolic NefFigure 6
Analysis and affinity purification of plant-produced cytosolic Nef. A: Samples of leaf protein homogenates from a p25 (line 120) 
and a p27 mut (line 116) transgenic line were resolved by 15% SDS-PAGE and subjected to immunoblot with anti-FLAG poly-
clonal antiserum. A dilution series of a recombinant, FLAG-tagged ScFv [28] was loaded as a quantitative reference. The aster-
isk indicates a non-specific, anti FLAG – immunoreactive peptide. Numbers at left indicate molecular weight markers in kDa. 
Co: control mock-transformed plant. B: Total leaf protein homogenate from transgenic plant line 116 expressing p27 mut was 
subjected to affinity chromatography with a cobalt resin. His-tagged Nef was eluted with imidazole. U: fraction not bound to 
the resin; W: wash fraction. Numbers at left indicate molecular weight markers in kDa.
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BMC Biotechnology 2007, 7:12 http://www.biomedcentral.com/1472-6750/7/12In all constructs (Figure 1) Nef encoding sequences were
under the control of the constitutive CaMV 35S promoter
and the nopaline synthase (NOS) terminator sequence.
To enhance translational efficiency, the Tobacco Mosaic
Virus (TMV) 5' leader sequence Ω [40] was fused in frame
with the Nef sequences. Moreover to facilitate the purifi-
cation and detection of the recombinant proteins, all Nef
coding sequences harbour at their 3'end the sequences
encoding the FLAG and polyhistidine-tag peptides, with
the exception of wild-type p27 Nef that only carried the
FLAG tag. All inserts were generated by overlap extension
PCR [41]. Briefly, a set of primers was used to generate by
PCR, using Pfu polymerase (Stratagene, La Jolla, CA), two
DNA fragments having overlapping ends. PCR-generated
DNA fragments were first purified from agarose gel using
GFX PCR DNA and Gel Band Purification Kit (Amersham
Bioscience) and then employed in a subsequent overlap
extension reaction to obtain the resulting fusion products.
To amplify the fusion products cloned in the constructs
p25 and p27 mut (Figure 1) the following forward prim-
ers were used BNFor (5' CGGGATCCATGAGACGAGCT-
GAGCCAGCAGCAGATG 3') and BNMFor (5'
CGGGATCCATGGCCGGCAAGTGGTCAAAAAGTAGT-
GTG 3'). The HSRev (5' TCCCCCGGGCTAATGGTGAT-
GGTGATGGTGCTTGTCGTC 3') was used as the reverse
primer. P27 mut construct contains a mutated form of the
p27 Nef, coding for a full-length protein in which the
myristoylation consensus sequence is abolished by the
substitution of the glycine residue in second position into
alanine. P25 and p27 mut HIV Nef variants were cloned
in the binary vector pBI121. To allow transient expression
by protoplast transfection, the DNA cassettes starting
from the CaMV 35S promoter and ending with the NOS
terminator sequence (Figure 1) were cloned into the vec-
tor pGEMR-4Z vector for transient expression.
For generation of the p27 construct, the Nef coding
sequence was amplified from plasmid pSCNef51 using
the P27 Xba1 Forward (5' CAGAGTCGTCTAGAGGT-
GGCAAGTGGTCAAAAAGT 3') and Nef Flag Reverse (5'
3') primers. The resulting PCR product was cloned into
the pDHA vector [42] for transient expression.
The PR1 signal peptide was amplified from plasmid
pDE300d [23] using the sPR1BamH1Forward (5'
CAGAGTCGGGATCCATGGGATTTTTTCTCTTTTC 3') and
sPR1Xba1Reverse (5' CAGAGTCGTCTAGACGCATGA-
GAAGAGTGAG 3') primers. To amplify the sp-Nef vari-
ants for cloning into pDHA, the following forward
primers were used: p25Xba1For (5' CAGAGTCGTCTA-
GAAGACGAGCTGAGCCAG 3') and P27Xba1For (5'
CAGAGTCGTCTAGAGGTGGCAAGTGGTCAAAAAGT 3').
The NefPst1Rev (5' CAGAGTCGCTGCAGCTAATGGT-
GATGGTGATG 3') was used as the reverse primer.
Plant transformation
The constructs p25 and p27 mut were electroporated into
A.tumefaciens strain LBA4404. Leaf discs of Nicotiana taba-
cum cv Petit Havana SR1, were transformed according to
the protocol described elsewhere [43].
Protoplast transfection
Protoplasts prepared from axenic leaves of tobacco were
subjected to polyethylene glycol-mediated transfections
exactly as described by [33]. 40 µg of each plasmid was
used to transform 106 protoplasts in 1 ml. After transfec-
tion, cells were incubated for 16 h at 25°C before meta-
bolic labelling.
In vivo labelling of protoplasts and analysis of expressed 
polypeptides
Pulse-chase experiments, immunoprecipitation, SDS-
PAGE and fluorography were performed as described pre-
viously [21]. Immunoprecipitation was performed with
anti FLAG antiserum (Sigma, 1:1000) or anti Nef
(EVA#3067.4, NIBSC-CFAR MRC) at a 1:1000 dilution.
ELISA detection and quantification of plant-expressed Nef 
variants
Expression of p25 and p27 mut Nef variants, in tobacco
plants, were determined by direct ELISA. TSP were
obtained as described: for each sample, 100 mg of leaf tis-
sue was ground thoroughly in liquid nitrogen and the
powder was added with 500 µl of PBS-buffer (PBS) con-
taining protease inhibitors (Complete EDTA Free,
ROCHE). Extracts were clarified by centrifugation at
20000 × g for 30 min at 4°C. ELISA assays were performed
coating 96-well microplates with 100 µl of total protein
extract for each sample, for 2 h at 37°C or O/N at 4°C.
E.coli recombinant Nef (EVA#650, NIBSC-CFAR MRC)
was used as positive control. The plates were blocked with
5% milk/PBS at 37°C for 2 h. After washing, plant recom-
binant Nef was detected using the HIV-1 Nef rabbit
Antiserum (Cat#2949 NIH AIDS Research and Reference
Reagent Program) [44] diluted 1:100 in PBS 2% milk, at
37°C for 2 h or O/N at +4°C, followed by incubation with
Biotin-Labeled Affinity Purified anti-rabbit IgG (Cat#16-
15-06 KPL) diluted 1:2500 and strepavidin-horseradish
peroxidase conjugate (RPN 1231 Amersham) diluted
1:2000, at 37°C for 2 h. The substrate was OPD (AGDIA
kit). The reaction was stopped after 1 h, by addition of 1/
2 volume of 3 M H2SO4 and the colorimetric reaction was
measured at 492 nm. Plant recombinant Nef levels,
expressed as% TSP, were estimated using, as standard
curve, different concentrations (ranging between 100 and
12.5 ng) of E.coli recombinant Nef (EVA#650, NIBSC-
CFAR MRC). The amount of total soluble proteins (TSP)
was estimated by Bradford assay. The OD value from each
sample was subtracted from control plant OD value.Page 10 of 12
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Leaf samples (10 mg) were ground in 50 µl of 1× SDS-
PAGE sample buffer and centrifuged at 12,000 × g for 10
min. The supernatants were boiled and loaded on 15%
SDS-PAGE (w/v) followed by immunoblotting with FLAG
antiserum (Sigma, UK). Signal was detected by ECL Plus
(Amersham).
Cobalt affinity purification of 6× histidine-tagged Nef
Leaves of a transgenic tobacco plant expressing p27 mut
were harvested and ground in liquid nitrogen. The sample
was thawed in the presence of lysis buffer (20 mM Tris-
HCl pH 8.0, 100 mM NaCl) + protease inhibitors (Com-
plete EDTA-free, Roche). The sample was centrifuged at
12,000 × g for 30 minutes at 4°C to pellet the debris. Puri-
fication was carried out in a batch method as detailed in
the manufacturer's instructions. Briefly, the clarified sam-
ple was added to 2 mls of Talon™ cobalt resin (Clontech)
sand mixed at room temperature for 30 minutes. The resin
was washed twice with 10 column volumes of lysis buffer
before being added to a plastic column. The resin was
washed with 2 column volumes of wash buffer (lysis
buffer + 10 mM imidazole). Proteins were eluted in 1 ml
fractions by the addition of elution buffer (lysis buffer +
50 mM imidazole). Fractions were analysed by SDS-PAGE
followed by immunoblotting with Flag antiserum (Sigma,
UK).
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